Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 17.91 is 198% above its 1-year average of 6.01, near the high end of its 1-year range (0.00–17.91).
As of the fiscal period ended Tuesday, June 30, 2026. 123.57% above its 12-month average of 8.01.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 17.91.
QUICK RATIO (ACID-TEST)
17.91
QUICK RATIO (ACID-TEST) AVG TTM
8.01
QUICK RATIO (ACID-TEST) AVG 3Y
N/A
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+123.57%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
+434.60%
vs the sector median at left
Parabilis Medicines, Inc.
Market Cap
$3.33B
Quick Ratio (Acid-Test)
17.91
TTM Avg
8.01
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.32B
Quick Ratio (Acid-Test)
4.72
TTM Avg
21.21
3Y Avg
17.30
5Y Avg
19.05
Market Cap
$3.39B
Quick Ratio (Acid-Test)
3.30
TTM Avg
3.01
3Y Avg
3.08
5Y Avg
4.22
Market Cap
$3.44B
Quick Ratio (Acid-Test)
9.61
TTM Avg
11.20
3Y Avg
9.88
5Y Avg
7.68
Market Cap
$3.21B
Quick Ratio (Acid-Test)
3.17
TTM Avg
4.10
3Y Avg
7.42
5Y Avg
12.78
Market Cap
$3.49B
Quick Ratio (Acid-Test)
10.45
TTM Avg
13.16
3Y Avg
14.41
5Y Avg
11.78
Market Cap
$3.49B
Quick Ratio (Acid-Test)
8.93
TTM Avg
9.13
3Y Avg
14.29
5Y Avg
16.91
Market Cap
$3.51B
Quick Ratio (Acid-Test)
21.02
TTM Avg
15.64
3Y Avg
20.34
5Y Avg
22.11
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Parabilis Medicines, Inc. (PBLS) | $3.33B | 17.91 | 8.01 | N/A | N/A |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.32B | 4.72 | 21.21 | 17.30 | 19.05 |
| CareDx, Inc (CDNA)vs › | $3.38B | 4.51 | 3.14 | 3.73 | 4.01 |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.39B | 3.30 | 3.01 | 3.08 | 4.22 |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | 9.61 | 11.20 | 9.88 | 7.68 |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.21B | 3.17 | 4.10 | 7.42 | 12.78 |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.49B | 10.45 | 13.16 | 14.41 | 11.78 |
| Celcuity Inc. (CELC)vs › | $3.49B | 8.93 | 9.13 | 14.29 | 16.91 |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.51B | 21.02 | 15.64 | 20.34 | 22.11 |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.53B | 50.82 | 11.65 | 9.40 | 9.07 |
Quick Ratio
17.91
Excludes inventory
Current Ratio
17.91
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 17.91 |
| 2026-03-31 | 6.12 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
